AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06003894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kegel exercises
Description: Kegel exercises; It is done by squeezing your pelvic floor muscles for 3 to 5 seconds and relaxing them. Participants are expected to do this exercise in the form of hold-relax 10-15 times each set. Participants are expected to practice Kegel exercises, 2 sets a day, 3 days a week for 8 weeks.
Study NCT06003894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 360 degree expanded diaphragmatic breathing training
Description: 360-degree expanded diaphragm breathing is the delivery of air taken during inspiration to the postero-lateral wall of the abdomen. Breathing in this way ensures that the pressure in the abdomen is distributed equally in all directions. Practices for using this breathing pattern will be done 2 sets per day, each set for 10 minutes.
Study NCT05851261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PA3670
Description: Placebo as control
Study NCT05851261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PA3670
Description: Placebo as control
Study NCT04791332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67953964
Description: JNJ-67953964 capsule will be administered orally.
Study NCT04791332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered orally.
Study NCT04221867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stricture dilation with CRE balloon
Description: Esophageal stricture is treated by dilation therapy.
Study NCT04221867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: Autologous fat graft is gathered and injected to stricture
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polatuzumab vedotin
Description: Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orelabrutinib
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax PO will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Venetoclax PO will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide PO will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chidamide
Description: Chidamide PO will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penpulimab
Description: Penpulimab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.
Study NCT06516978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.
Study NCT06523920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution + cold storage
Description: Preservation of the free flap with UW solution and cold storage during ischemia time
Study NCT06523920 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Unperfused free flap under warm ischemia
Description: Traditional processing of the free flap: no perfusion of the flap and warm ischemia (room temperature conservation during ischemia time
Study NCT06295484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alternating traditional CPAP, NIPPV, and high CPAP
Description: The investigators will continue to record the Edi signals during the 3 methods (traditional CPAP, NIPPV, and high CPAP)
Study NCT05355246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assisted sit-up exercises
Description: Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and maximum of 10 repetitions, two times a day and two days a week. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting treatment session.
Study NCT05355246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: swiss ball pikes exercises
Description: Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend her hips and try to pull her feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting the treatment session.
Study NCT04840693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood, urine, saliva
Study NCT04840693 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples
Description: blood, urine, saliva
Study NCT04840693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complications
Description: bone mineral density, diabetes, hypertension, quality of life (quality of life questionnaire SF-36)
Study NCT04840693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Complications
Description: bone mineral density, diabetes, hypertension, quality of life (quality of life questionnaire SF-36)
Study NCT04931706 — intervention group
Intervention type: OTHER
Intervention: Magnetics Assisted by Singe port
Description: Use of magnet for assistance through the surgery, and a novel approach as it is single port
Study NCT04634253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT04634253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3462817
Description: Given IV
Study NCT04308291 — intervention group
Intervention type: DEVICE
Intervention: MiniMed™ 780G System
Description: Subject enrolled in the study will start using the MiniMed™ 780G pump in Auto Mode after a run-in period of two weeks in Manual Mode (with no SmartGuard™ functions). Study phase in Automode will follow a 6 and 12 months follow- up as per standard of care.
Study NCT05679869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masking Sound
Description: Prerecorded environmental noise and masking sounds played from headphones
Study NCT05679869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No masking sound
Description: Prerecorded environmental noise but no masking sounds played from headphones
Study NCT05086107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for infusion
Study NCT05479019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual stimuli
Description: Stimuli will be shown to participants and they will be asked to perform a visual task.
Study NCT04591808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin/Perindopril
Description: 1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.
Study NCT04591808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.
Study NCT04591808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: 1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.
Study NCT05847946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape application and Core stabilization home program
Description: Participants in the kinesiotape group will receive 2 sessions of kinesiotape per week, in addition to the core stabilization home program, 5 days a week for 4 weeks.
Study NCT05847946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization home program
Description: Core stabilization exercises will be given to the participants as a home exercise program.
Study NCT05379998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: Sciatic nerve mobilization (sliding technique) will be performed by a physical therapist. The sciatic nerve mobilization technique improves the nerve mobility of the hemiparetic lower limb in a nervous system patient and is helpful in increasing the ROM of the lower limbs without resistance.
Study NCT05379998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF hold relax technique
Description: Proprioceptive neuromuscular facilitation hold relaxation technique of hamstring muscle will be performed by the physical therapist three days a week for 6 weeks. In the hold relax technique after reaching the point of resistance, an isometric contraction is performed against the resistance to get a pain free response.
Study NCT05474157 — intervention group
Intervention type: OTHER
Intervention: Standard care treatment for COVID-19 in Intensive Care Unit
Description: Standard care for ARDS patients consisted of respiratory support, intravenous fluid therapy, medical treatment including anticoagulation and sedation, nutrition, change of position every 4 hours and if needed, hemodynamic support.
Study NCT06125717 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H1 influenza antigen
Description: Either 7.5 μg or 15 μg of the H1 influenza antigen
Study NCT06125717 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H1 influenza antigen
Description: Either 7.5 μg or 15 μg of the H1 influenza antigen
Study NCT05824819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Next Generation Sequencing (NGS)
Description: Biological materials (stool, peritoneal/ovarian cyst fluid, endometrial aspirate) will be secured and then subjected to molecular analysis using the Next Generation Sequencing (NGS) method. The stages will include: i) isolation of bacterial DNA from biological materials, ii) preparation of libraries for sequencing, including the performance of the PCR and nested-PCR methods on bacterial DNA isolates from the tested samples of biological materials, iii) purification of amplification products, indexing, validation of the concentration of amplicons, pooling and denaturation of libraries, iv) standardization and optimization of the procedure for the isolation of bacterial metagenomic DNA from biological materials from intestines, peritoneal cavity, uterine cavity and endometrial tissues, v) standardization of the nested-PCR method on bacterial DNA isolates from the tested biological materials, vi) submission of samples for sequencing.
Study NCT04840823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxacin
Description: Oral 200mg tablet
Study NCT04840823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet
Study NCT06400043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive dual-task
Description: Participants will be asked to walk at comfortable walking speed while playing an additional cognitive task, namely the Stroop Color and Word Test.
Study NCT06400043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor dual-task
Description: Participants will be asked to walk at comfortable walking speed while playing an additional motor task, namely a game that requires arm swing to hit the targets.
Study NCT05105204 — intervention group
Intervention type: DEVICE
Intervention: ArteVu
Description: The study participants will concurrently undergo noninvasive blood pressure monitoring with the ArteVu finger clip applied to the same extremity that is being used to measure the radial artery pressure.
Study NCT05451901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate necrosectomy
Description: Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the immediate necrosectomy group, endoscopic necrosectomy (EN) will be performed in the same session of EUS-guided drainage using a gastroscope. The endoscope is inserted into the WON cavity through the LAMS, and necrotic tissue is removed using biopsy forceps, snare, or basket catheter. The EN procedures will be repeated until clinical improvement.
Study NCT05451901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Step-up approach
Description: Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the step-up approach group, an additional interventional procedure will be withheld for 72-96 hours after initial EUS-guided drainage. In cases without clinical improvement after 72-96 hours, additional drainage will be permitted, which includes increasing the number of stents, additional EUS-guided drainage, and performing percutaneous drainage (step-up treatment). Insufficient improvement even after two times of step-up treatment allows subsequent endoscopic necrosectomy (EN).
Study NCT05503823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS or tRNS and TMS
Description: A light electrical current will be applied to the scalp of the participants via 2 electrodes. The resting and active motor threshold will be measured before, right after, after 30 minutes, and after 1 hour of receiving the tACS or tRNS.
Study NCT05103046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCT-03-008
Description: Orally available kinase inhibitor
Study NCT06491485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group M (lidocaine with Magnesium sulfate)
Description: a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with magnesium sulfate 50 mg/kg (maximum 2g) will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
Study NCT06491485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B (lidocaine with Sodium bicarbonate)
Description: a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with 50 ml 4.2% sodium bicarbonate will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
Study NCT06491485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C (lidocaine with saline)
Description: a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
Study NCT06383481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile based education
Description: Control Group Patients in the control group will be provided with standard patient care and information. No application will be made.~Experimental group The mobile application will be downloaded to the phones of patients who can use the mobile application. The mobile application will be available to the patient. Patients will be informed about daily monitoring of the mobile application, following the training steps, and that they can reach the researcher with consultancy services whenever they need. The mobile application will be made available to patients within a 12-week period and patient follow-up will be provided.
Study NCT05952882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide + Metformin
Description: Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week. Concomitantly, Liraglutide was initiated at a subcutaneous dose of 0.6 mg once daily for 1 week, then titrated in increments of 0.6 mg once daily every 1 to 3 weeks to a maintenance dose of 3.0 mg once daily for up to 12 weeks
Study NCT05952882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week
Study NCT04922385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).
Study NCT06513091 — intervention group
Intervention type: DEVICE
Intervention: OCS Lung
Description: The TransMedics Organ Care System (OCS) Lung is an FDA approved portable extracorporeal lung perfusion and monitoring system.
Study NCT06655844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sana Pain Reliever
Description: The Sana Pain Reliever (Sana PR) by Sana Health Inc is a device comprised of one (1) main component (Mask with Earbuds) and two (2) ancillary components (Charger and Headband). The device is worn over the eyes (with earbuds in ears).
Study NCT06655844 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham SPR
Description: Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 15 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.